Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Pre-viously Untreated Extensive-Stage Small-Cell Lung Cancer: A Systematic Review and Network Me-ta-analysis
Not Applicable
- Conditions
- Extensive stage small cell lung cancer
- Registration Number
- JPRN-UMIN000041702
- Lead Sponsor
- Showa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3879
Inclusion Criteria
Not provided
Exclusion Criteria
non-small cell lung cancer patients Poor performance status (3 or more) Patients previously treated with systemic anticancer therapy
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method progression free survival Incidence of Grade 3 or higher any adverse events Incidence of Grade 3 or higher neutropenia, anemia, and thrombocytopenia